Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Fosmanogepix in Healthy Subjects
NCT02957929Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fosmanogepix in fungal infection (5 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoint: Safety and tolerability of single and multiple oral doses of APX001 at 21 days. Started Oct 2016; status: completed.
02
Drugs
fosmanogepix
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT02957929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957929.